Daniel P. Petrylak, MD

Daniel P. Petrylak, MD

Yale Cancer Center

New Haven, CT

Daniel P. Petrylak, MD completed his medical degree at Case Western Reserve University School of Medicine, and completed his internal medicine residency at Albert Einstein College of Medicine/Jacobi Medical center and fellowship at Memorial SloanKettering cancer center. He is currently Director of Genitourinary Oncology, and Co Director of the Signal Transduction Program at Yale University Cancer Center. Dr. Petrylak is involved in clinical trials research on a local, national, and international level. He is the head of the advanced bladder subcommittee in the Southwest Oncology Group Genitourinary Committee. Dr. Petrylak served as PI or Co PI on 7 Southwest Oncology Group Protocols. Most notably, he served as the PI for a randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone in men with hormone refractory prostate cancer. This trial was one of two studies that demonstrated a survival benefit for docetaxel-based therapy in men with advanced prostate cancer. This trial supported the approval of docetaxel for hormone refractory prostate cancer by the FDA. He also help to design and served as principal investigator for the SPARC trial, an international registration trial evaluating the activity of satraplatin as a second line therapy for hormone refractory prostate cancer. Dr. Petrylak is a recognized international leader in the field. He has served on the program committee for the annual meetings of the American Urological Association (2003-11) as well as for the American Society of Clinical Oncology (1995-7, 2001-3). He also has served as a committee member for the Devices and Immunolgicals section of the Food and Drug Administration. He has published extensively in the New England Journal of Medicine, Journal of Clinical Oncology, Journal of the National Cancer Institute, as well as Cancer Research and Clinical Cancer Research.

Articles by Daniel P. Petrylak, MD

New Targets for Advanced Bladder Cancer

Daniel P. Petrylak, MD, discusses the efficacy of checkpoint inhibitors in previously cisplatin treated metastatic urothelial carcinoma patients and the need for better biomarkers for checkpoint proteins. He also identifies future directions for treating the disease, including ipilimumab/nivolumab and epacadostat/ pembrolizumab combinations, and PD-L1 immunohistochemical staining.

Read More

Beyond Checkpoint Inhibition: New Therapeutic Approaches to Bladder Cancer

Dr. Daniel P. Petrylak presented “Beyond Checkpoint Inhibition: New Therapeutic Approaches to Bladder Cancer” at the International Bladder Cancer Update meeting on Tuesday, January 24, 2017.     Keywords: bladder cancer, chemotherapy, docetaxel, MTOR,  TORC1, TORC2, TSC, VEGFR  How to cite: Petrylak, Daniel P.  “Beyond Checkpoint Inhibition: New Therapeutic Approaches to Bladder Cancer” January 24, 2017. Accessed Mar 2018. https://grandroundsinurology.com/beyond-checkpoint-inhibition Transcript Beyond Checkpoint Inhibition: New Therapeutic Approaches to Bladder Cancer There are some patients of course who can’t receive cisplatin-based therapy, but not all patients are eligible for immune therapy. If they’ve had autoimmune diseases, if they’ve had psoriasis that requires that they go on systemic therapy, if...

Read More

Join the GRU Community

- Why Join? -